William Blair Investment Management LLC Acquires 10,440 Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)

William Blair Investment Management LLC boosted its holdings in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 2.2% in the fourth quarter, Holdings Channel reports. The firm owned 485,268 shares of the specialty pharmaceutical company’s stock after purchasing an additional 10,440 shares during the quarter. William Blair Investment Management LLC’s holdings in ANI Pharmaceuticals were worth $26,826,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. JPMorgan Chase & Co. raised its stake in shares of ANI Pharmaceuticals by 159.3% in the third quarter. JPMorgan Chase & Co. now owns 554,835 shares of the specialty pharmaceutical company’s stock valued at $33,101,000 after acquiring an additional 340,854 shares during the last quarter. Global Alpha Capital Management Ltd. boosted its holdings in shares of ANI Pharmaceuticals by 1.8% in the 3rd quarter. Global Alpha Capital Management Ltd. now owns 536,450 shares of the specialty pharmaceutical company’s stock worth $32,005,000 after acquiring an additional 9,500 shares in the last quarter. Thompson Siegel & Walmsley LLC boosted its holdings in shares of ANI Pharmaceuticals by 17.6% in the 3rd quarter. Thompson Siegel & Walmsley LLC now owns 230,159 shares of the specialty pharmaceutical company’s stock worth $13,731,000 after acquiring an additional 34,416 shares in the last quarter. Thrivent Financial for Lutherans boosted its holdings in shares of ANI Pharmaceuticals by 2.3% in the 3rd quarter. Thrivent Financial for Lutherans now owns 13,028 shares of the specialty pharmaceutical company’s stock worth $777,000 after acquiring an additional 299 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its holdings in shares of ANI Pharmaceuticals by 3.7% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 250,346 shares of the specialty pharmaceutical company’s stock worth $14,936,000 after acquiring an additional 8,869 shares in the last quarter. Institutional investors own 76.05% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have recently commented on ANIP. JPMorgan Chase & Co. began coverage on ANI Pharmaceuticals in a report on Wednesday, March 12th. They issued an “overweight” rating and a $85.00 target price on the stock. Guggenheim boosted their target price on ANI Pharmaceuticals from $84.00 to $86.00 and gave the stock a “buy” rating in a report on Wednesday, March 5th. Leerink Partnrs raised ANI Pharmaceuticals to a “strong-buy” rating in a report on Wednesday, December 11th. StockNews.com raised ANI Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, March 14th. Finally, HC Wainwright restated a “buy” rating and issued a $94.00 price objective on shares of ANI Pharmaceuticals in a research report on Monday. Two investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $79.75.

Insider Buying and Selling at ANI Pharmaceuticals

In other ANI Pharmaceuticals news, SVP Krista Davis sold 1,000 shares of the company’s stock in a transaction on Friday, February 21st. The shares were sold at an average price of $60.20, for a total transaction of $60,200.00. Following the completion of the sale, the senior vice president now owns 68,624 shares in the company, valued at approximately $4,131,164.80. The trade was a 1.44 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, VP Meredith Cook sold 400 shares of the company’s stock in a transaction on Thursday, March 13th. The shares were sold at an average price of $63.33, for a total transaction of $25,332.00. Following the sale, the vice president now owns 80,545 shares of the company’s stock, valued at $5,100,914.85. The trade was a 0.49 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 3,200 shares of company stock worth $191,776. Insiders own 12.70% of the company’s stock.

ANI Pharmaceuticals Stock Performance

ANIP stock opened at $64.22 on Wednesday. The company has a 50 day moving average price of $58.79 and a 200 day moving average price of $58.07. The stock has a market capitalization of $1.40 billion, a PE ratio of -116.76 and a beta of 0.63. ANI Pharmaceuticals, Inc. has a fifty-two week low of $52.50 and a fifty-two week high of $70.81. The company has a debt-to-equity ratio of 1.52, a current ratio of 2.74 and a quick ratio of 1.97.

ANI Pharmaceuticals Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.